Tag Archives: Novartis

29Mar/18

2006-2017 CBER Approved Therapies and Biological Products

Cancer Drug R&D and Market Trends from 2006 to 2017

March 29, 2018Drug Discovery Research, Newsantibody development, Antibody Discovery, CAR-T, Novartis, Therapeutic Antibodybiolabs

Great Achievements Have Been Made in Cancer Drug Listing In 2006-2017, a total of 89 oncology therapies (NTDs) were approved by the Center for Drug Evaluation and Research (CDER). The Biologics EvaluationRead More…

24Jul/17

The First CAR-T Therapy Drug Is Approved and Recommended by FDA Experts Unanimously on a 10-0 Vote!

July 24, 2017Immunotherapy Research, NewsCAR-T, FDA, immunotherapy drug, Novartisbiolabs

Novartis’ chimeric antigen receptor T cell therapy (CAR-T) was supported and approved unanimously (10-0) on July 12th by the U.S. FDA Advisory Committee experts. This vote marks the key milepost of thisRead More…

22Jun/17

Will the First CAR-T Therapy Be Approved on July 12? —Novartis CTL019

June 22, 2017Immunotherapy Research, NewsCAR-T, CAR-T therapy, CTL019, Novartisbiolabs

On July 12, FDA experts will discuss whether CAR-T CTL019 can be on the market, which is an assessment of the CTL019 Biologics License Application (BLA) submitted by Novartis and will evaluateRead More…